2026 DB Healthcare Summit Takes: Tools & Biopharma Services

We hosted several companies at the 2026 DB Healthcare Summit with representation across both Tools, Biopharma Services and Occupational Health. The commentary from company meetings was indicative of a continued industry recovery, a central theme across biomedical research and the drug development value chain. Company specific commentary included anecdotes on capacity ramping, end-market momentum, and key wins albeit KPIs on 2027 were relatively mum despite investor inquiries. We also discussed the AI Use Cases and Adoption Across R&D and Clinical Development with pharma and CRO industry thought leaders; in-short, while evidence for the potential of AI-based deflationary pressure across the clinical trial process is building, the true impact is both: a) likely to come in lower than today's projections;